These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
568 related articles for article (PubMed ID: 32485573)
1. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo. Han B; Geng H; Liu L; Wu Z; Wang Y Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573 [TBL] [Abstract][Full Text] [Related]
2. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224 [TBL] [Abstract][Full Text] [Related]
3. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway. Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877 [TBL] [Abstract][Full Text] [Related]
4. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation. Hyeon S; Lee H; Yang Y; Jeong W Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472 [TBL] [Abstract][Full Text] [Related]
5. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss. Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069 [TBL] [Abstract][Full Text] [Related]
6. Treatment with hydrogen molecules prevents RANKL-induced osteoclast differentiation associated with inhibition of ROS formation and inactivation of MAPK, AKT and NF-kappa B pathways in murine RAW264.7 cells. Li DZ; Zhang QX; Dong XX; Li HD; Ma X J Bone Miner Metab; 2014 Sep; 32(5):494-504. PubMed ID: 24196871 [TBL] [Abstract][Full Text] [Related]
7. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways. Chen G; Xu Q; Dai M; Liu X Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598 [TBL] [Abstract][Full Text] [Related]
8. Macrolactin A protects against LPS-induced bone loss by regulation of bone remodeling. Sapkota M; Gao M; Li L; Yang M; Shrestha SK; Choi H; Soh Y Eur J Pharmacol; 2020 Sep; 883():173305. PubMed ID: 32673673 [TBL] [Abstract][Full Text] [Related]
9. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production. Lee SY; Lee KS; Yi SH; Kook SH; Lee JC PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641 [TBL] [Abstract][Full Text] [Related]
10. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species. Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464 [TBL] [Abstract][Full Text] [Related]
11. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis. Ye X; Jiang J; Yang J; Yan W; Jiang L; Chen Y Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1080-1089. PubMed ID: 35929595 [TBL] [Abstract][Full Text] [Related]
12. Estrogen-related receptor γ negatively regulates osteoclastogenesis and protects against inflammatory bone loss. Kim HJ; Kim BK; Ohk B; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR J Cell Physiol; 2019 Feb; 234(2):1659-1670. PubMed ID: 30076703 [TBL] [Abstract][Full Text] [Related]
13. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189 [TBL] [Abstract][Full Text] [Related]
14. Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways. Cheng J; Zhou L; Liu Q; Tickner J; Tan Z; Li X; Liu M; Lin X; Wang T; Pavlos NJ; Zhao J; Xu J J Cell Physiol; 2018 Mar; 233(3):2502-2512. PubMed ID: 28771720 [TBL] [Abstract][Full Text] [Related]
15. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways. Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570 [TBL] [Abstract][Full Text] [Related]
16. Rubiadin-1-methyl ether from Morinda officinalis How. Inhibits osteoclastogenesis through blocking RANKL-induced NF-κB pathway. He YQ; Zhang Q; Shen Y; Han T; Zhang QL; Zhang JH; Lin B; Song HT; Hsu HY; Qin LP; Xin HL; Zhang QY Biochem Biophys Res Commun; 2018 Dec; 506(4):927-931. PubMed ID: 30392907 [TBL] [Abstract][Full Text] [Related]
17. Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice. Cao J; Wang S; Wei C; Lin H; Zhang C; Gao Y; Xu Z; Cheng Z; Sun WC; Wang HB Int Immunopharmacol; 2021 Jan; 90():107137. PubMed ID: 33199235 [TBL] [Abstract][Full Text] [Related]
18. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation. Han SY; Lee KH; Kim YK Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB. Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671 [TBL] [Abstract][Full Text] [Related]
20. Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression. Han SY; Kim YK Am J Chin Med; 2019; 47(2):439-455. PubMed ID: 30827151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]